Gemita 1000mg/26.3mg Injection
Marketer
Fresenius Kabi India Pvt Ltd
Salt Composition
Gemcitabine (1000mg) + Mannitol (26.3mg)
Overview Gemita 1000mg/26.3mg Injection
Oncaspar (1000mg/26.3mg) injection is a prescription medication indicated for treating various cancers, including non-small cell lung, breast, pancreatic, bladder, and ovarian cancers. Its mechanism involves inhibiting cancer cell proliferation and aiding in tumor regression. Administration must be carried out by a qualified healthcare professional; self-injection is strongly discouraged. Report any known allergies to this medication to your physician immediately. Potential side effects may include nausea, vomiting, alopecia, anemia (low red blood cell count), and leukopenia (low white blood cell count). Pre- and/or during-treatment blood tests may be required. Supplements may be prescribed to mitigate medication-induced deficiencies. A diet rich in fruits and vegetables is also recommended. Disclose any other medications, pregnancy, breastfeeding, or existing medical conditions to your doctor. This medication is contraindicated during breastfeeding. Alcohol consumption should be avoided during treatment. Operating machinery or driving is strictly prohibited while undergoing treatment with Oncaspar.
Uses of Gemita 1000mg/26.3mg Injection
Malignant neoplasm
Major Benefits of Gemita 1000mg/26.3mg Injection:
Administering this medication will be done by your physician or their associate; self-medication is strictly prohibited.
Common Side effects of Gemita 1000mg/26.3mg Injection:
- Nausea
- Vomiting
- Diarrhea
- Decreased blood cells (red cells, white cells, and platelets)
- Rash
- Increased liver enzymes
- Blood in urine
- Protein in urine
- Breathlessness
How to use Gemita 1000mg/26.3mg Injection:
Administering this medication will be handled by your healthcare provider; self-medication is strictly prohibited.
How Gemita 1000mg/26.3mg Injection works:
Gemita, a 1000mg/26.3mg injectable formulation, comprises gemcitabine and mannitol. Gemcitabine inhibits cancer cell proliferation by disrupting DNA and RNA synthesis, effectively blocking their growth and replication. Mannitol, a non-reactive osmotic diuretic, increases urine output by promoting renal water excretion. Its osmotic properties also find application in reducing intraocular pressure or cerebral edema.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent use of Gemita 1000mg/26.3mg Injection and alcohol can result in increased sleepiness.
PregnancyCONSULT YOUR DOCTOR
Administering Gemita 1000mg/26.3mg Injection during pregnancy poses a confirmed risk to fetal development and is therefore contraindicated. Nevertheless, in exceptional, life-threatening circumstances, a physician might deem its use justifiable if the potential benefits outweigh the known hazards. Always seek medical advice before use.
Breast feedingUNSAFE
Administration of Gemita 1000mg/26.3mg Injection is contraindicated while breastfeeding due to potential infant toxicity. Evidence indicates a risk of harm to the nursing infant.
DrivingUNSAFE
The injectable medication Gemita 1000mg/26.3mg can induce drowsiness, blurred vision, and dizziness. Refrain from driving if you experience these effects.
KidneySAFE IF PRESCRIBED
The use of Gemita 1000mg/26.3mg Injection in patients with kidney impairment appears to pose minimal risk. Current evidence indicates dose modification for Gemita 1000mg/26.3mg Injection might be unnecessary in such cases. However, medical advice is recommended.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of Gemita 1000mg/26.3mg Injection to individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Gemita 1000mg/26.3mg Injection :
NA
Facts to Know About Gemita 1000mg/26.3mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Treatment | Cancer Medications |
3,018 People bought this recently